Metastatic renal cell carcinoma (mRCC) has a dismal prognosis. Effective prognostic and predictive factors are needed. A higher haemoglobin (Hb) / red cell distribution width (RDW) ratio is known to be related to better outcomes. Here we evaluated the prognostic value of the Hb/RDW ratio in pre-treated mRCC patients receiving nivolumab.
This is a sub-analysis of the retrospective Meet-URO 15 study, on pre-treated patients with mRCC, receiving nivolumab. The first objective was to investigate the prognostic role of Hb/RDW ratio, in terms of overall survival (OS) and progression-free survival (PFS).
356 were included in the present analysis. Patients were mainly males with a median age of 63 years. We classified patients in high and low Hb/RDW ratio, according to two different cut-offs: 0.9frequently used in literature, and 0.7, result of the time-dependent AUC analysis.. Median OS and PFS were 22.3 months (95 %CI 19.4-29.0) and 5.6 months (95 %CI 4.74.-7.53), respectively. At univariable analysis, higher Hb/RDW ratio was related to longer OS (p < 0.001) and PFS (p = 0.011); the multivariable model confirmed only the association between a Hb/RDW ratio ≥ 0.7 and better OS.
The Hb/RDW ratio is a manageable and practical prognostic tool in patients with cancer; its prognostic value for OS was confirmed in pre-treated mRCC patients, receiving nivolumab, only using a cut-off value derived from a time-dependent AUC.
Cancer treatment and research communications. 2025 Apr 26 [Epub ahead of print]
Giulia Claire Giudice, Sara Elena Rebuzzi, Giulia Mazzaschi, Federica Pecci, Michele Maffezzoli, Alessandro Acunzo, Letizia Gnetti, Enrico Maria Silini, Giuseppe Caruso, Elena Rapacchi, Pasquale Rescigno, Giuseppe Fornarini, Giuseppe Luigi Banna, Sebastiano Buti
Medical Oncology Unit, University Hospital of Parma, Parma, Italy; Department of Medicine and Surgery, University of Parma, Parma, Italy., Medical Oncology Unit, Ospedale San Paolo, Savona, Italy., Department of Medicine and Surgery, University of Parma, Parma, Italy; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Medical Oncology Unit, University Hospital of Parma, Parma, Italy; Department of Medicine and Surgery, University of Parma, Parma, Italy. Electronic address: ., Pathology Unit, University Hospital of Parma, Parma, Italy., Department of Medicine and Surgery, University of Parma, Parma, Italy; Pathology Unit, University Hospital of Parma, Parma, Italy., Medical Oncology Unit, University Hospital of Parma, Parma, Italy., Translational and Clinical Research Institute, Centre for Cancer, Newcastle University, Newcastle Upon Tyne, United Kingdom; Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy., Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genova, Italy., Portsmouth Hospitals University NHS Trust, Portsmouth, PO6 3LY, United Kingdom; Faculty of Science and Health, School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, PO1 2UP, United Kingdom.